Canakinumab for anakinra-intolerant Schnitzler syndrome

Key Findings

• ●Rapid improvement after first canakinumab dose
• ●After failure of colchicine, prednisone, methotrexate, dapsone

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 01:59 PMby pubmed-api

   Matched to a PubMed record by title + author during Issue-3 backfill; PMID and DOI resolved from PubMed E-utilities.

   tools: pubmed.esummary